These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 24432457)

  • 1. Experts add second drug to breast cancer prevention regimen.
    Harv Womens Health Watch; 2013 Oct; 21(2):8. PubMed ID: 24432457
    [No Abstract]   [Full Text] [Related]  

  • 2. Women's decision making about whether or not to use breast cancer chemoprevention.
    Altschuler A; Somkin CP
    Women Health; 2005; 41(2):81-95. PubMed ID: 16219589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen for breast cancer.
    Karn A; Jha AK; Shrestha S; Acharya B; Poudel S; Bhandari RB
    JNMA J Nepal Med Assoc; 2010; 49(177):62-7. PubMed ID: 21180225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caring for the breast cancer survivor.
    Abdel-Razeq H
    Am J Med; 2011 Feb; 124(2):e11; author reply e13. PubMed ID: 21295181
    [No Abstract]   [Full Text] [Related]  

  • 5. Can endocrine treatment for hormone-positive premenopausal women with early breast cancer replace adjuvant chemotherapy?
    Malayeri R
    J Clin Oncol; 2003 Jun; 21(12):2444-5; author reply 2446-7. PubMed ID: 12805348
    [No Abstract]   [Full Text] [Related]  

  • 6. Keeping breast cancer at bay. Women at risk are asked to weigh the pros and cons of a prevention pill.
    Brink S
    US News World Rep; 1999 May; 126(21):76. PubMed ID: 10387894
    [No Abstract]   [Full Text] [Related]  

  • 7. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer drugs should be offered to healthy but high risk women, US panel concludes.
    McCarthy M
    BMJ; 2013 Apr; 346():f2499. PubMed ID: 23599364
    [No Abstract]   [Full Text] [Related]  

  • 9. Bilateral swollen eyelids occurring during adjuvant treatment with tamoxifen for early breast cancer.
    Jaspers H; Blaisse R; Maessen-Visch B; Mattijssen V
    Neth J Med; 2009 Jun; 67(6):245-6. PubMed ID: 19749398
    [No Abstract]   [Full Text] [Related]  

  • 10. Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!
    Samur M; Bozcuk HS
    J Clin Oncol; 2003 Jun; 21(12):2444; author reply 2445-7. PubMed ID: 12805349
    [No Abstract]   [Full Text] [Related]  

  • 11. Combo drug therapy doubles breast cancer survival rates. Early treatment with Tamoxifen-chemotherapy combination often extends life.
    Health News; 2005 Aug; 11(8):3-4. PubMed ID: 16184637
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of advanced breast cancer: How much chemotherapy is enough?
    DiPaola RS; Kaufman A; Mikhail MM
    Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
    [No Abstract]   [Full Text] [Related]  

  • 13. [Adjuvant for breast cancer chemo-endocrine therapy].
    Taguchi T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):453-67. PubMed ID: 9530350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.
    Ryan PD; Goss PE
    Nat Clin Pract Oncol; 2005 Dec; 2(12):596-7. PubMed ID: 16341095
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
    Jordan VC
    Eur J Cancer; 2006 Nov; 42(17):2909-13. PubMed ID: 17064889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
    Kaufmann M; Jonat W; Hilfrich J; Eidtmann H; Gademann G; Zuna I; von Minckwitz G
    J Clin Oncol; 2007 Jul; 25(19):2664-70. PubMed ID: 17563395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
    Schilder CM; Schagen SB
    Minerva Ginecol; 2007 Aug; 59(4):387-401. PubMed ID: 17923830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer consensus meetings: vive la difference?
    Davidson NE; Levine M
    J Clin Oncol; 2002 Apr; 20(7):1719-20. PubMed ID: 11919226
    [No Abstract]   [Full Text] [Related]  

  • 20. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.